Evidence map›Paper›PMID 33422940›Full record

ArticleBiomaterials2021

Immune checkpoint inhibition in syngeneic mouse cancer models by a silicasome nanocarrier delivering a GSK3 inhibitor.

Sean D Allen, Xiangsheng Liu, Jinhong Jiang, Yu-Pei Liao, Chong Hyun Chang, Andre E Nel, Huan Meng

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Nanoparticles for cancer therapy: a review of influencing factors and evaluation methods for biosafety.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  19. Nanocarriers for cancer nano-immunotherapy.Drug delivery and translational research · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sean D AllenDepartment of Medicine, Division of NanoMedicine, University of California, Los Angeles, CA, USA.
Xiangsheng LiuDepartment of Medicine, Division of NanoMedicine, University of California, Los Angeles, CA, USA; California NanoSystems Institute, University of California, Los Angeles, CA, USA.
Jinhong JiangDepartment of Medicine, Division of NanoMedicine, University of California, Los Angeles, CA, USA.
Yu-Pei LiaoDepartment of Medicine, Division of NanoMedicine, University of California, Los Angeles, CA, USA.
Chong Hyun ChangDepartment of Medicine, Division of NanoMedicine, University of California, Los Angeles, CA, USA.
Andre E NelDepartment of Medicine, Division of NanoMedicine, University of California, Los Angeles, CA, USA; California NanoSystems Institute, University of California, Los Angeles, CA, USA. Electronic address: anel@mednet.ucla.edu.
Huan MengDepartment of Medicine, Division of NanoMedicine, University of California, Los Angeles, CA, USA; California NanoSystems Institute, University of California, Los Angeles, CA, USA. Electronic address: menghuan@g.ucla.edu.
University of California, Los Angeles · USCalifornia NanoSystems Institute · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Use of a Nano-Enabled Platform for Pancreatic Cancer ImmunotherapyR01CA247666 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEL, ANDRE ELIAS, ZINK, JEFFREY I · 2020 to 2024
$2.6M
UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of Pancreas CancerU01CA198846 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DONAHUE, TIMOTHY R, MENG, HUAN · 2015 to 2019
$2.4M
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA247666NCI NIH HHS U01 CA198846
6 · The paper itself

Abstract

Checkpoint blocking antibodies that interfere in the PD-1/PD-L1 axis provide effective cancer immunotherapy for tumors that are immune inflamed or induced to become "hot". It has also been demonstrated that a small molecule inhibitor of the signaling hub kinase GSK3 can interfere in the PD-1/PD-L1 axis in T-cells by suppressing PD-1 expression. This provides an alternative approach to intervening in the PD-1/PD-L1 axis to provide cancer immunotherapy. In this communication, we demonstrate the remote loading of GSK3 inhibitor AZD1080 into the porous interior of mesoporous silica nanoparticles coated with a lipid bilayer (a.k.a. silicasomes). In a MC38 colon cancer model, intravenous injection (IV) of silicasome-encapsulated AZD1080 significantly improved biodistribution and drug delivery to the tumor site. The improved drug delivery was accompanied by cytotoxic MC38 tumor cell killing by perforin-releasing CD8

Indexed as

AnimalsCD8-Positive T-LymphocytesCell Line, TumorDrug CarriersGlycogen Synthase Kinase 3Immune Checkpoint InhibitorsImmunotherapyMiceNanoparticlesNeoplasmsSilicon DioxideTissue DistributionDrug CarriersGlycogen Synthase Kinase 3Immune Checkpoint InhibitorsSilicon DioxideGSK3 inhibitorImmune checkpointNano drug deliveryPD-1/PD-L1 axisSilicasomeSolid tumor

Identifiers

PMID33422940
PMCPMC7870571
OpenAlexW3117412968

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.